Solentim Ltd Embraces CRISPR And Other Rapid Gene-Editing Technologies With Horizon Discovery Ltd.
BOURNEMOUTH, England--(BUSINESS WIRE)--Solentim, the developer of the world-leading imager for single cell cloning in the upstream cell line development workflow, is pleased to announce the purchase of its Cell Metric™ CLD system for monoclonality verification by Horizon Discovery Group plc (”Horizon”) (AIM: HZD), a leading provider of research tools to support translational genomics and the development of personalized medicines.
Horizon provides a range of off-the-shelf disease model cell lines, as well as services to develop cell lines for their clients all over the world. They are at the cutting edge of novel gene-editing techniques including ZFN, rAAV and CRISPR.
Help employers find you! Check out all the jobs and post your resume.